Intralipid (Soya Oil, Purified)

Soybean oil in Intralipid provides triglyceride particles that are broken down by lipoprotein lipase in the bloodstream. This releases free fatty acids, which serve as an energy source, contribute to cell‑membrane synthesis, and deliver essential fatty acids such as linoleic and alpha‑linolenic acids that the body cannot produce.

The dose of Intralipid is individualized. A prescribing clinician determines the volume and infusion rate based on the patient’s caloric requirements, lipid needs, serum triglyceride levels, and overall clinical condition. No fixed regimen is provided in public information.

The pregnancy category for Intralipid is listed as unknown. Use during pregnancy or lactation should be based on a careful risk‑benefit assessment by the treating physician, considering the nutritional needs of the mother and fetus or infant.

To order Intralipid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Intralipid is a soybean‑oil‑based emulsion, whereas alternatives such as ClinOleic or SMOFlipid contain mixtures of soybean, olive, fish, or medium‑chain triglycerides. These newer formulations aim to reduce inflammation and improve fatty‑acid profiles, but Intralipid remains widely used for its established efficacy, availability, and cost‑effectiveness.

Intralipid should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or vigorously shake the emulsion, as this can damage the lipid particles and affect safety and efficacy.

Intralipid is given by intravenous infusion using aseptic technique. It is typically administered through a dedicated line or Y‑site with a controlled infusion pump, following the prescribed rate to avoid rapid lipid overload. Compatibility with other IV drugs should be checked before co‑administration.

The most serious risks include fat overload syndrome, severe hypertriglyceridemia, anaphylactic reactions, pulmonary embolism from lipid droplets, and hepatic dysfunction. Monitoring triglyceride levels, observing for allergic signs, and adhering to recommended infusion rates help mitigate these risks.

Intralipid is contraindicated in patients with known hypersensitivity to soy or egg proteins, severe hypertriglyceridemia, disorders of fat metabolism (e.g., lipoprotein lipase deficiency), and in those with acute pancreatitis related to high triglyceride levels. Clinicians should evaluate each case before initiating therapy.